Deprescribing Bisphosphonates
Project: Deprescribing Bisphosphonates in Older Nursing Home Residents with Dementia
Grant Number: National Institutes on Aging 1K08AG071794-01
Led by Dr. Joshua Niznik, this study seeks to evaluate the risks and benefits of deprescribing versus continuing bisphosphonates in older nursing home residents with Alzheimer’s Disease (AD) and AD-Related Dementias (AD/ADRD). This study will evaluate the qualitative perceptions of providers and caregivers, clinical outcomes, and healthcare-related costs to determine whether deprescribing bisphosphonates is a safe and reasonable strategy to reduce the medication burden for certain individuals in this population.
Role
Primary Investigator
Read more about this study on the NIH Reporter
Publications
Niznik JD, Ernecoff NC, Thorpe CT, Mitchell SL, Hanson LC. Operationalizing deprescribing as a component of goal-concordant dementia care. J Am Geriatr Soc. [published online ahead of print, 2022 Dec 22.]
Niznik JD, Gilliam MA, Colón-Emeric C, Thorpe CT, Lund JL, Berry SD, Hanson LC. Controversies in Osteoporosis Treatment of Nursing Home Residents. J Am Med Dir Assoc. 2022 Dec;23(12):1928-1934. PMC9885478.
Niznik JD, Gilliam MA, Li X, Aspinall SL, Hanson LC, Kelley CJ, Thorpe CT. Patterns of oral bisphosphonate deprescribing in older nursing home residents with dementia. Osteoporosis Int. 2022 Feb;33(2):379-390. PMC8813888
Niznik JD, Li X, Gilliam MA, Hanson LC, Aspinall SL, Colon-Emeric C, Thorpe CT. Are Nursing Home Residents With Dementia Appropriately Treated for Fracture Prevention? J Am Med Dir Assoc. 2021 Jan;22(1):28-35.e3. PMC8358966